Thomas Mourez1, Constance Delaugerre2, Muriel Vray3, Véronique Lemée4, François Simon5, Jean-Christophe Plantier6. 1. Normandie Université, France; Université de Rouen, Institut de Recherche et d'Innovation Biomédicale (IRIB), Equipe d'Accueil 2656, F-76183 Rouen, France; CHU de Rouen, Laboratoire de Virologie Associé au Centre National de Référence du VIH, F-76031 Rouen, France. 2. Université Denis Diderot Paris 7, F-75010 Paris, France; AP-HP, hôpital Saint-Louis, Laboratoire de Virologie, F-75010 Paris, France. 3. Institut Pasteur, Unité d'Epidémiologie des Maladies Emergentes, F-75014 Paris, France. 4. CHU de Rouen, Laboratoire de Virologie Associé au Centre National de Référence du VIH, F-76031 Rouen, France. 5. Université Denis Diderot Paris 7, F-75010 Paris, France; AP-HP, hôpital Saint-Louis, Laboratoire de Virologie, F-75010 Paris, France. Electronic address: Francois.Simon@sls.aphp.fr. 6. Normandie Université, France; Université de Rouen, Institut de Recherche et d'Innovation Biomédicale (IRIB), Equipe d'Accueil 2656, F-76183 Rouen, France; CHU de Rouen, Laboratoire de Virologie Associé au Centre National de Référence du VIH, F-76031 Rouen, France. Electronic address: Jean-Christophe.Plantier@univ-rouen.fr.
Abstract
BACKGROUND: An improved version of the bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 has been introduced to overcome the underquantification observed with previous versions, especially with non-B HIV-1 subtypes. OBJECTIVES: Comparing bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 versus Roche Cobas CA/CTM v2.0 and Abbott RealTime HIV-1 assays for HIV-1 group M and non-M (N, O, P) viral load measurement. STUDY DESIGN: The three assays were tested in parallel on 103HIV-1 group M plasma samples, and on non-group M HIV-1 culture supernatants. RESULTS: Values obtained for the 103HIV-1 group M plasma samples tested with bioMérieux assay showed good overall correlation compared to the 2 others. The Roche Cobas assay gave higher values than the bioMérieux assay, while Abbott and bioMérieux both displayed similar results. However, analysis showed a wider dispersion in results when comparing the bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 and the other 2 techniques. All data taken into account, we observed frequent discrepancies in quantification, of the plasma samples and major differences above 1log in 10/72 (13.8%). The quantification of non-M HIV groups in culture supernatant has shown variable results, with better quantification of HIV-O and of HIV-N respectively with the Abbott assay and the bioMérieux assay. CONCLUSIONS: The bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 showed improved sensitivity to non-B HIV-M subtypes compared to previous versions. Notwithstanding, we observed frequent discrepancies and a wide dispersion in results when comparing bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 and the other 2 techniques.
BACKGROUND: An improved version of the bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 has been introduced to overcome the underquantification observed with previous versions, especially with non-B HIV-1 subtypes. OBJECTIVES: Comparing bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 versus Roche Cobas CA/CTM v2.0 and Abbott RealTime HIV-1 assays for HIV-1 group M and non-M (N, O, P) viral load measurement. STUDY DESIGN: The three assays were tested in parallel on 103HIV-1 group M plasma samples, and on non-group M HIV-1 culture supernatants. RESULTS: Values obtained for the 103HIV-1 group M plasma samples tested with bioMérieux assay showed good overall correlation compared to the 2 others. The Roche Cobas assay gave higher values than the bioMérieux assay, while Abbott and bioMérieux both displayed similar results. However, analysis showed a wider dispersion in results when comparing the bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 and the other 2 techniques. All data taken into account, we observed frequent discrepancies in quantification, of the plasma samples and major differences above 1log in 10/72 (13.8%). The quantification of non-M HIV groups in culture supernatant has shown variable results, with better quantification of HIV-O and of HIV-N respectively with the Abbott assay and the bioMérieux assay. CONCLUSIONS: The bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 showed improved sensitivity to non-B HIV-M subtypes compared to previous versions. Notwithstanding, we observed frequent discrepancies and a wide dispersion in results when comparing bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 and the other 2 techniques.
Authors: Mary A Rodgers; Ana S Vallari; Julie Yamaguchi; Vera Holzmayer; Barbara Harris; Coumba Toure-Kane; Souleymane Mboup; Samar Badreddine; Carole McArthur; Nicaise Ndembi; Dora Mbanya; Lazare Kaptue; Gavin Cloherty Journal: AIDS Res Hum Retroviruses Date: 2018-02-13 Impact factor: 2.205